Ethris GmbH
Ethris GmbH is a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines using proprietary RNA and lipidoid nanoparticle technology platforms.
Classification
Profile
Funding
Funding details not yet available.
Next-generation RNA therapeutics and vaccines using proprietary mRNA stabilization and lipidoid nanoparticle delivery technology to enhance therapeutic efficacy.
B2B, pharmaceutical partners, healthcare providers, research institutions
- Up-front licensing fees - €25 M from AstraZeneca (2017) and similar deals for other targets. [2]
channel partners
Big-pharma collaborators - AstraZeneca (SNIM RNA deal), Bayer (investor & co-development) · Non-profit & governmental funders - CEPI, EU Horizon, Gates Foundation (grant financing) · Contract manufacturing organizations (CMOs) - specialized spray-drying partners for scale-out
R&D for RNA technology and clinical preparation for lead candidate ETH47, supported by recent $5 million funding.
Proprietary RNA and lipidoid nanoparticle technology platforms, intellectual property, and clinical-stage development pipeline.
Developing innovative RNA therapies and vaccines, focusing on delivering stabilized mRNAs and preparing lead candidate ETH47 for clinical trials.
Co-development partnerships - joint R&D teams, shared data rooms, and milestone-based governance that keep partners deeply engaged · Grant stewardship - regular reporting to funders, public data releases, and community-impact communication to maintain goodwill · Scientific thought-leadership - publishing results, open-source data where appropriate,
Competes with other biotech firms in RNA therapeutics; differentiates through specialized stabilization and lipidoid delivery platforms for enhanced mRNA performance.
Limitations in current RNA delivery methods and mRNA stability, which this technology addresses to improve therapeutic outcomes in vaccines and treatments.
- Diversify revenue before product launch - develop a licensing-as-a-service (LaaS) model where pharma pays a subscription for ongoing acce
Which geographic markets (EU, US, Asia) are you prioritizing for partnership outreach? · Do you have in-house GMP manufacturing capacity, or will you rely entirely on CMOs? · Are you targeting product-sale revenue within the next 3 years, or will the model remain partnership-centric for a longer horizon?
- Funding depth: Over $80 M raised across 11 rounds, with a recent €11.33 M EU grant (2025) and $5 M CEPI vaccine grant, demonstrates stron
No investors recorded yet.
Sources & references
Web verified · 0 sourcesSource URLs will appear here after the next enrichment run.